Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2696 - The influence of body composition on the systemic exposure of paclitaxel in esophageal cancer patients


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Oesophageal Cancer


Lena Van Doorn


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


L. Van Doorn1, H.N. Rier2, J.L.A. van Vught3, C. van Kesteren4, S. Bins1, R.H.J. Mathijssen1, M. Levin2, S.L.W. Koolen1

Author affiliations

  • 1 Medical Oncology, Erasmus MC Cancer Institute, 3015 CE - Rotterdam/NL
  • 2 Department Of Internal Medicine, Albert Schweitzer Hospital, 3318 AT - Dordrecht/NL
  • 3 Department Of Surgery, Erasmus MC, University Medical Center, 3015 CE - Rotterdam/NL
  • 4 Department Of Pharmacy, Albert Schweitzer Hospital, 3318 AT - Dordrecht/NL


Abstract 2696


Weight loss and malnutrition are common symptoms of esophageal cancer, which can lead to skeletal muscle wasting and loss of adipose tissue. It was hypothesized before that the pharmacokinetics (PK) of chemotherapy may depend on body composition (Prado et al, 2013). In addition, we earlier showed that the clearance (CL; L/h) of unbound paclitaxel (pac) is related to body-surface area (BSA; m2) and gender (Bins et al, 2014). Therefore, now we aimed to assess the relationship between pac CL and body composition.


We analyzed 197 patients with stage III esophageal cancer who were treated with pac and carboplatin in a prospective study between 2008 and 2013. CL of pac, which was estimated using nonlinear mixed effects modeling (NONMEM) was used as a measure of systemic pac exposure (de Graan et al, 2012). Skeletal muscle index (SMI, cm2/m2), muscle attenuation (MA) and visceral adipose tissue (VAT; cm2) were measured at the level of the 3rd lumbar vertebra on computed tomography (CT) scans performed before treatment. Gender-specific differences in pac CL, based on the 1st quartile and the 4th quartile of the SMI and VAT measurement were analyzed with a Mann-Whitney test. A Spearman rank correlation (r) was calculated to explore the relationship between pac CL and SMI, VAT and MA, respectively.


CT images and pac PK data were available for 183 patients (78% was men). Pac CL was correlated with SMI (r = .27, p = .001) and VAT (r = .28, p = .001), while no correlation was found with MA (r < .01, p = .91). Interestingly, while in male patients with the highest SMI a higher pac CL was found compared to the lowest SMI (p = .024), and also for the 1st and 4th quartile of VAT (p = .003), in female patients no effect of SMI and VAT on pac CL was seen.


Skeletal muscle mass and visceral adipose tissue are positively correlated with pac CL in male patients with esophageal cancer. Differences in body composition between men and women may potentially explain the difference in the outcome of this analysis, and may also partly explain the difference in pac CL between both genders. Although the effect sizes are too small to support dose adaptions based on VAT or SMI, these parameters partly explain the large interpatient variability in pac PK.

Clinical trial identification

Not applicable

Legal entity responsible for the study

Erasmus MC Cancer Institute




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.